Connect Biopharma Holdings Limited Payments to Acquire Debt Securities, Available-for-sale
Connect Biopharma Holdings Limited (CNTB) reported Payments to Acquire Debt Securities, Available-for-sale of $4.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-12
- Connect Biopharma Holdings Limited payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $4.47M, a 43.49% decline year-over-year.
- Connect Biopharma Holdings Limited payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Connect Biopharma Holdings Limited payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Connect Biopharma Holdings Limited payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00.
- Connect Biopharma Holdings Limited payments to acquire debt securities, available-for-sale for fiscal 2025 was $30.47M, a 97.20% increase from fiscal 2024.
- Connect Biopharma Holdings Limited payments to acquire debt securities, available-for-sale for fiscal 2024 was $15.45M, a 50.20% decline from fiscal 2023.
- Connect Biopharma Holdings Limited payments to acquire debt securities, available-for-sale for fiscal 2023 was $31.03M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.47M 10-Q · filed 2026-08-12 | $4.47M derived: sum of 3 quarters · filed 2026-08-12 | $4.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $7.91M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $7.91M derived: sum of 3 quarters · filed 2026-08-12 | $30.47M 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $7.91M derived: sum of 2 quarters · filed 2026-08-12 | $30.47M 10-Q · filed 2025-11-12 | $45.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $30.47M 10-Q · filed 2026-08-12 | $45.92M derived: sum of 3 quarters · filed 2026-08-12 | $45.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $22.56M 10-Q · filed 2026-05-12 | $38.01M derived: sum of 2 quarters · filed 2026-05-12 | $38.01M derived: sum of 3 quarters · filed 2026-05-12 | $38.01M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $15.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $15.45M derived: sum of 2 quarters · filed 2026-03-31 | $15.45M derived: sum of 3 quarters · filed 2026-03-31 | $15.45M 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $31.03M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |